Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 12/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4155358 | 0.89 | PTGER1 (0.52) | PTGER1PTGER3 | |
| SCHEMBL4159777 | 0.89 | PTGER1 (0.47) | PTGER1PTGER3GAACYP1A2CYP3A4 | |
| SCHEMBL4159115 | 0.86 | HTT (0.52) | PTGER1PTGER3ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4164383 | 0.85 | MEN1 (0.49) | PTGER1PTGER3GAAALDH1A1CYP1A2 | |
| SCHEMBL4163073 | 0.84 | L3MBTL1 (0.48) | PTGER1PTGER3GAAALDH1A1 | |
| SCHEMBL4165897 | 0.84 | PTGER1 (0.49) | PTGER1PTGER3GAAALDH1A1CYP1A2 | |
| SCHEMBL4173995 | 0.82 | PTGER1 (0.44) | PTGER1PTGER3GAACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL4160798 | 0.82 | PTGER1 (0.44) | PTGER1PTGER3GAACYP1A2CYP3A4 | |
| SCHEMBL3203502 | 0.81 | PTGER1 (0.45) | PTGER1GAAALDH1A1CYP3A4 | |
| SCHEMBL4162628 | 0.81 | PTGER1 (0.55) | PTGER1PTGER3ALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2001872-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113289-A1 | BENZOFURAN COMPOUNDS AS EP1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099169-A1 | Benzofuran Compounds As EP1 Receptor Antagonists | PTGER1, PTGER2, PTGER3 | PTGER1 1/4885PTGER3 3/4885GAA 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.